(Q40860325)

24 September 2017

title

Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir (English)

1 reference

24 September 2017

1 reference

1 reference

D F Smee

1

1 reference

24 September 2017

K W Bailey

series ordinal

2

1 reference

24 September 2017

R W Sidwell

series ordinal

3

1 reference

24 September 2017

publication date

1 July 2000

1 reference

Antiviral Chemistry & Chemotherapy

24 September 2017

published in

1 reference

24 September 2017

volume

11

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

303-309

1 reference

Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Progressive Vaccinia Treated with Ribavirin and Vaccinia Immune Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020001100406

10.1177/095632020001100406

21 January 2018

Identifiers

DOI

1 reference

24 September 2017

1 reference